BioMarin Pharmaceutical revenue and financials

BMRN · NASDAQ · USD

$56.22−2.29%−$1.32

Close · October 6, 2026

In the fiscal year ended December 2025, BioMarin Pharmaceutical reported revenue of $3.22B (+12.87% year over year). Net income was $348.9M, a net margin of 10.8%.

Annual revenue · 2025: $3.22B
  1. $1.12B2016
  2. $1.31B2017
  3. $1.49B2018
  4. $1.7B2019
  5. $1.86B2020
  6. $1.85B2021
  7. $2.1B2022
  8. $2.42B2023
  9. $2.85B2024
  10. $3.22B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+12.87%
2025 vs 2024
Net income growth
−18.26%
2025 vs 2024
Net margin
10.8%
2024: 15.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue990766875776825745747746712649646581
Cost of revenue398374349550311310310373314330344319
Gross profit592392526227514435438372398319302262
Selling, general and administrative309250324268232206267253263226260216
Research and development207179192409161———————
Operating income209138197-46.727722416111412078.527.330.5
EBIT209138197-46.727722416111412078.527.330.5
EBITDA307154210-28.229524618513314710654.156.2
Interest expense63.315.02.82.62.72.92.63.03.63.56.13.8
Pre-tax income61.4141-27.2-26.329823817013413210619.341.7
Income tax16.635.719.44.457.352.444.728.425.016.9-1.01.3
Net income44.8106-46.6-30.724118612510610788.720.440.4
Net income to common shareholders44.8106-46.6-30.724118612510610788.720.440.4
Basic EPS0.230.55-0.24-0.161.250.970.660.560.560.470.110.21
Diluted EPS0.230.54-0.24-0.161.230.950.640.550.550.460.090.21
Average shares (basic)193192192192192191191190190189188188
Average shares (diluted)194198192192197196197197201199192191